This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
News & Press: General News

ABN guidance on COVID19 and MS therapies

11 March 2020  
Share |

Coronavirus (COVID 19) has dominated headlines in recent weeks, with the number of cases in the UK continuing to rise. Older people and those with pre-existing medical conditions are more likely to become severely ill.

Our understanding of coronavirus is developing rapidly but there is concern that a variety of immunosuppressive therapies used in the treatment of a range of neurological disorders might predispose patients to contract coronavirus or increase the severity of infections.

The ABN MS and Neuroimmunology Advisory Group has prepared advice on the use of MS treatments based on current knowledge. This guidance will be kept under review as our understanding of the virus develops. Further guidance on the use of other immunosuppressive therapies for a range of immunological conditions will be issued shortly. 

To view the guidance please click here.


Contact Us

Association of British Neurologists
Ormond House
27 Boswell Street
London
WC1N 3JZ

Telephone: +44 (0)20 7405 4060
Email: info@abn.org.uk

Registered Charity No. 1077893
Company No. 3816842

Follow Us